Q-omics provides the consensus-scored TSPYL2 profile across patient tissues and cancer cell-line models. TSPYL2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TSPYL2 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, TSPYL2 RNA expression shows 18,740 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, BLCA, and UVM as cancer lineages where TSPYL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPYL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPYL2 survival associations across molecular data types. TSPYL2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPYL2 RNA expression–survival associations across cancer types. High TSPYL2 expression shows unfavorable associations in KIRP, KICH, LUSC and COAD, but favorable associations in UCEC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for TSPYL2 RNA expression.
This table summarizes TSPYL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPYL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPYL2 shows lower tumor expression in BLCA, LUAD and LUSC and higher tumor expression in KIRC, LIHC and HNSC. The BLCA box plot shows higher TSPYL2 RNA expression in normal versus tumor tissue (log2 FC = −2.311, t-test p < 0.001).
This table shows molecular features associated with TSPYL2 in patient tissues and cancer cell lines. In patient samples, TSPYL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPYL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
